Source: Annual Congress 2009 - Treatment of lung cancer

Abstract

Background: The expression of Bcl-2 oncoprotein is associated with inhibition of apoptosis and prolonged cell survival. The purpose of this study was to investigate Bcl-2 protein expression in patients with small-cell lung cancer (SCLC) in order to see if it was related to clinicopathological features and to prognosis.
Materials and methods: Forty patients with SCLC were stained immunohistochemically using specific monoclonal antibody (DAKO-Bcl-2, 124). Bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of neoplastic cells.
Results: Immunopositivity was present in 26 (60%) of SCLC patients. Twenty-three of 40 (57,5 %) patients had limited disease at presentation, and 17 of 40 (42,5 %) had extensive disease. There was not any correlation with Bcl-2 protein expression and clinicopathological parameters such as sex, age, smoking history, performance status and tumour differentiation. According to the extent of the disease, Bcl-2 expression was significantly higher in patients with extensive disease (p<0,009). Bcl-2 expression was associated with significant shorter survival in patients with SCLC (Log Rank = -5.26; p=0.00001). Cox regression analysis controlling for age, sex and tumor stage, confirmed that Bcl-2 expression (HR= 0,049 p<0,0001) and N stage (HR=0,152 p<0,012) were an independent prognostic markers for poor prognosis.

Rating:

Share or cite this content

Citations should be made in the following way:
B. Ilievska Poposka, S. Atanasova, T. Stefanovski, S. Smickova, G. Petrusevska (Skopje, Fyrom). Bcl-2 as a prognostic factor for survival in small-cell lung cancer. Eur Respir J 2009; 34: Suppl. 53, 2659

Member's Comments

No comment yet.

Related content which might interest you: Apelin expression is a prognostic factor in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Effects of prognostic factors on survival of the patients of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005 Procalitonin: A prognosis factor in lung cancer and a marker for small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: A 5-year-follow-up study Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 HER2/Neu overexpression as independent negative prognostic factor for non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Source: Eur Respir J 2001; 17: 660-666 Year: 2001 Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 669s Year: 2007 Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Trail receptors as prognostic factors in non-small cell lung cancer Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004 Is gender a prognostic factor in long term survival non-small cell lung cancer? Source: Eur Respir J 2002; 20: Suppl. 38, 185s Year: 2002 Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Prognostic factors in non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Staging of lung cancer Year: 2010